The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd has announced the formation of a Clinical Advisory Board for its PromarkerEso blood test, aimed at detecting esophageal adenocarcinoma. This board, composed of leading clinicians and researchers, will provide strategic guidance to support the global commercialization of PromarkerEso, a test that addresses a significant health issue given the rising prevalence of esophageal adenocarcinoma worldwide. The board’s expertise is expected to enhance the company’s research, development, and commercial efforts, positioning Proteomics International as a leader in the field of esophageal cancer diagnostics.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on developing innovative diagnostic tools. The company is known for its world-first diagnostic blood test, PromarkerEso, which is designed to detect esophageal adenocarcinoma, a prevalent type of esophageal cancer.
YTD Price Performance: -47.50%
Average Trading Volume: 130,994
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$55.02M
Find detailed analytics on PIQ stock on TipRanks’ Stock Analysis page.